[1]Zhang Luxia,Long Jianyan,Jiang Wenshi.et al.Trends in Chronic Kidney Disease in China.New England Journal of Medicine,2016 Sep 1;375(9):905-6.doi:10.1056/NEJMc1602469.[2]Ton J.Rabelink, Dick de Zeeuw.The glycocalyx-linking albuminuriawith renal and cardiovascular disease [J]. Nat Rev Nephrol, 2015,11 (11): 667-676.[3]Hong-Xia Shang,Jun-Yu Zhao, Xue Shen,et al.The efficacy and safety of sulodexide in patients with diabetic nephropathy:a meta-analysis of randomized controlled trials.Int J Clin Exp Med 2016;9(7):12481-12491.[4]Gambaro G, Kinalska I, Oksa A, et al.Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol, 2002, 13: 1615-1625. [5]Angelo A. Bignamini,Ahmed Chebil,Giovanni Gambaro.et al.Sulodexide for Diabetic-Induced Disabilities:A Systematic Review and Meta-Analysis.Adv Ther (2021)38:1483-1513.https://doi. org/10.1007/s12325-021-01620-1.